Preliminary preclinical trials suggest that the administration of hIDPSCs can restore the expression of BDNF, DARPP32, and D2R, promoting neuroprotection and neurogenesis in an HD rat model (Wenceslau et al., 2022). This evidence concerns the gene BDNF and Huntington disease.